From: Systemic and cardiac susceptibility of immune compromised mice to doxorubicin
2 weeks | |||||||
---|---|---|---|---|---|---|---|
BASELINE | CONTROL | DOXORUBICIN | |||||
Parameter | Unit | MEAN | SE | MEAN | SE | MEAN | SE |
LVAW;d | mm | 0.83 | 0.04 | 0.83 | 0.04 | 0.99* | 0.15 |
LVAWS;s | mm | 1.08 | 0.06 | 1.10 | 0.04 | 1.33* | 0.15 |
LVID;d | mm | 3.25 | 0.08 | 3.59 | 0.11 | 2.64* | 0.22 |
LVID;s | mm | 2.16 | 0.08 | 2.55 | 0.14 | 1.53* | 0.24 |
LVPW;d | mm | 0.79 | 0.05 | 0.92 | 0.08 | 1.04* | 0.07 |
LVPW;s | mm | 1.00 | 0.05 | 1.08 | 0.04 | 1.26* | 0.11 |
Cardiac Output | ml/min | 11.94 | 0.91 | 14.71 | 1.30 | 6.82* | 1.32 |
Ejection Fraction | % | 67.72 | 1.78 | 57.87 | 3.73 | 76.10 | 6.35 |
Fractional Shortening | % | 36.94 | 1.33 | 30.05 | 2.51 | 45.31 | 6.28 |
Heart Rate | BPM | 381 | 18 | 471 | 21 | 352 | 23 |
Stroke Volume | ul | 30.62 | 1.56 | 31.30 | 2.33 | 18.91* | 3.18 |
Volume;d | ul | 45.62 | 2.74 | 54.64 | 4.53 | 26.40* | 5.53 |
Volume;s | ul | 15.00 | 1.47 | 23.34 | 3.47 | 7.49* | 2.86 |
N = 8 m, 4f | N = 4 m, 2f | N = 4 m, 2f |